If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Forteo ® (teriparatide [rDNA origin] injection)
20-mcg daily dose in a 2.4-mL prefilled delivery device
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
FORTEO® (teriparatide [rDNA origin] injection): Bone Mineral Density Response
Forteo significantly increased lumbar spine, femoral neck, and total hip BMD from baseline in PMW and men with osteoporosis and in patients with GIO.
Effects of Teriparatide on BMD in Postmenopausal Women With Osteoporosis
Results from a LOCF analysis showed that teriparatide significantly increased baseline to endpoint BMD at the LS, FN, and TH in postmenopausal women with osteoporosis.1
Table 1. Mean Percentage Change in BMD From Baseline to Endpointa in Postmenopausal Women With Osteoporosis Treated With Teriparatide for a Median of 19 Months 1
|
|
Teriparatide n=541 |
Placebo n=544 |
|
LS BMD |
9.7%b |
1.1% |
|
FN BMD |
2.8%c |
-0.7% |
|
TH BMD |
2.6%c |
-1.0% |
Abbreviations: BMD = bone mineral density; FN = femoral neck; LS = lumbar spine; TH = total hip.
a Intent-to-treat analysis, last observation carried forward.
b p<.001 compared with placebo.
c p<.05 compared with placebo.
In a subset of women for whom data were available at every time point (3, 6, 12, and 18 months; n=129), teriparatide significantly increased LS BMD by 3.9% at 3 months of treatment and 11.8% at 18 months.2
Effects of Teriparatide on BMD in Men With Primary or Hypogonadal Osteoporosis
Using a LOCF analysis, results showed that teriparatide treatment, for a median of 10 months, significantly increased baseline LS BMD by 5.9% compared to placebo (p<.001). Significant increases in LS BMD were seen at 3 months.1
Teriparatide treatment significantly increased FN BMD by 1.5% from baseline compared to the placebo group (p<.05).1
There was no significant difference observed in the change from baseline to endpoint TH BMD.1
Effects of Teriparatide on BMD in Men and Women With Glucocorticoid-Induced Osteoporosis
Results from a LOCF analysis showed that teriparatide significantly increased baseline to endpoint BMD at the LS, FN, and TH by 7.2%, 3.7%, and 3.6%, respectively, at the 18-month endpoint (p<.001 at all sites).1
Enclosed Prescribing Information
FORTEO® (teriparatide [rDNA origin] injection), Lilly
1. Forteo [package insert]. Indianapolis IN: Eli Lilly and Company; 2019.
2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Glossary
BMD = bone mineral density
FN = femoral neck
LS = lumbar spine
LOCF = last observation carried forward
TH = total hip
Date of Last Review: January 28, 2020
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 8am - 7pm ET
